Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial - Tanaka, Atsushi; Shimabukuro, Michio; Machii, Noritaka; Teragawa, Hiroki; Okada, Yosuke; Shima, Kosuke R.; Takamura, Toshinari; Taguchi, Isao; Hisauchi, Itaru; Toyoda, Shigeru; Matsuzawa, Yasushi; Tomiyama, Hirofumi; et al. (Journal of Diabetes Investigation, 2020)